Brief: Corbus Pharmaceuticals Presents Results Of Two Pre-Clinical Studies
02/11/2023 12:34
Nov 2 (Reuters) - Corbus Pharmaceuticals Holdings Inc
CRBP.O :
* CORBUS PHARMACEUTICALS PRESENTS RESULTS OF TWO
PRE-CLINICAL
STUDIES ON ITS ANTI-ΑVΒ8 MONOCLONAL ANTIBODY (CRB-601) AT THE
2023 SITC ANNUAL MEETING
* CORBUS PHARMACEUTICALS HOLDINGS INC - SUBMITTING
INVESTIGATIONAL
NEW DRUG APPLICATION FOR CRB-601 BY END OF 2023
Source text for Eikon: ID:nGNX5mlc2n
Further company coverage: CRBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corbus Pharmaceuticals Holdings
See all newsU.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Corbus gains on weight-loss data for obesity drug in early-stage study